[HTML][HTML] Fractionated doses of gemtuzumab ozogamicin (GO) combined to standard chemotherapy (CT) improve event-free and overall survival in newly-diagnosed …
S Castaigne, C Pautas, C Terre, E Raffoux… - Blood, 2011 - Elsevier
Abstract 6 Aim. GO is a potent antibody-directed chemotherapy against CD33 antigen. Two
MRC and SWOG Phase 3 studies have compared standard CT alone or combined with one …
MRC and SWOG Phase 3 studies have compared standard CT alone or combined with one …
Phase II pilot trial of gemtuzumab ozogamicin (GO) as first line therapy in acute myeloid leukemia patients age 65 or older
C Nabhan, LM Rundhaugen, MB Riley, A Rademaker… - Leukemia research, 2005 - Elsevier
The prognosis of acute myeloid leukemia (AML) in older adults is generally poor. Standard
cytotoxic chemotherapy is usually poorly tolerated and provides dismal results in this patient …
cytotoxic chemotherapy is usually poorly tolerated and provides dismal results in this patient …
The addition of gemtuzumab ozogamicin to low-dose Ara-C improves remission rate but does not significantly prolong survival in older patients with acute myeloid …
AK Burnett, RK Hills, AE Hunter, D Milligan, WJ Kell… - Leukemia, 2013 - nature.com
The treatment of older patients with acute myeloid leukaemia, who are not considered
suitable for conventional intensive therapy, is unsatisfactory. Low-dose Ara-C (LDAC) has …
suitable for conventional intensive therapy, is unsatisfactory. Low-dose Ara-C (LDAC) has …
Fractionated gemtuzumab ozogamicin and standard dose cytarabine produced prolonged second remissions in patients over the age of 55 years with acute myeloid …
S Pilorge, S Rigaudeau, F Rabian… - American Journal of …, 2014 - Wiley Online Library
Gemtuzumab ozogamicin (fGO), a humanized anti‐CD33 monoclonal antibody linked to
calicheamicin in combination with intensive chemotherapy gives high response rates in …
calicheamicin in combination with intensive chemotherapy gives high response rates in …
Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia
AK Burnett, NH Russell, RK Hills, J Kell… - Journal of clinical …, 2012 - ascopubs.org
Purpose There has been little survival improvement in older patients with acute myeloid
leukemia (AML) in the last two decades. Improving induction treatment may improve the rate …
leukemia (AML) in the last two decades. Improving induction treatment may improve the rate …
[HTML][HTML] Induction therapy of AML with ara-C plus daunorubicin versus ara-C plus gemtuzumab ozogamicin: a randomized phase II trial in elderly patients
U Brunnberg, M Mohr, R Noppeney, HA Dürk… - Annals of oncology, 2012 - Elsevier
Background Chemotherapy for elderly patients with acute myeloid leukemia (AML) results in
a median overall survival (OS) of≤ 1 year. Elderly patients often present with cardiac …
a median overall survival (OS) of≤ 1 year. Elderly patients often present with cardiac …
A phase 2 trial of azacitidine and gemtuzumab ozogamicin therapy in older patients with acute myeloid leukemia
S Nand, M Othus, JE Godwin… - Blood, The Journal …, 2013 - ashpublications.org
This trial tested the safety and efficacy of a regimen consisting of hydroxyurea followed by
azacitidine, 75 mg/m2 for 7 days, and gemtuzumab ozogamicin, 3 mg/m2 on day 8, in older …
azacitidine, 75 mg/m2 for 7 days, and gemtuzumab ozogamicin, 3 mg/m2 on day 8, in older …
Comparative efficacy and safety of gemtuzumab ozogamicin monotherapy and high-dose cytarabine combination therapy in patients with acute myeloid leukemia in …
LH Leopold, MS Berger, SC Cheng… - Clinical advances in …, 2003 - europepmc.org
Gemtuzumab ozogamicin was recently approved in the United States for the treatment of
older patients with CD33-positive acute myeloid leukemia (AML) in first relapse. However …
older patients with CD33-positive acute myeloid leukemia (AML) in first relapse. However …
Gemtuzumab ozogamicin with cytarabine and mitoxantrone as a third-line treatment in a poor prognosis group of adult acute myeloid leukemia patients: a single …
G Specchia, D Pastore, P Carluccio, G Spinosa… - Annals of …, 2007 - Springer
We analyzed the safety and efficacy of gemtuzumab ozogamicin (GO) combined with
cytarabine and mitoxantrone in the treatment of 21 patients with acute myeloid leukemia (11 …
cytarabine and mitoxantrone in the treatment of 21 patients with acute myeloid leukemia (11 …
Randomized trial of two schedules of low‐dose gemtuzumab ozogamicin as induction monotherapy for newly diagnosed acute myeloid leukaemia in older patients …
S Amadori, S Suciu, D Selleslag, R Stasi… - British journal of …, 2010 - Wiley Online Library
This study compared two schedules of low‐dose gemtuzumab ozogamicin (GO) as induction
monotherapy for untreated acute myeloid leukaemia in older patients unfit for intensive …
monotherapy for untreated acute myeloid leukaemia in older patients unfit for intensive …